Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2NIH 2INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 69Neoplasms 20Neoplasm Metastasis 12Brain Neoplasms 4Stomach Neoplasms 2Recurrence 2Osteitis Deformans 2Inflammatory Breast Neoplasms 2Head and Neck Neoplasms 2HER2 Positive Metastatic Breast Cancer 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1HER2-positive Advanced Breast Cancer 1HER2+ Metastatic Breast Cancer (MBC) 1HER-2 Gene Amplification 1Glioma 1Glioblastoma 1Diarrhea 1Carcinoma 1Breast Diseases 1Advanced Solid Tumors 1Adenocarcinoma 1

Interventions

Capecitabine 77pembrolizumab 70Oxaliplatin 68Cisplatin 56Fluorouracil 52Paclitaxel 41Trastuzumab 37Nivolumab 35Leucovorin 27Docetaxel 27Irinotecan 22Ramucirumab 20Gemcitabine 15Bevacizumab 15S 1 (combination) 14Carboplatin 13atezolizumab 12apatinib 12fludarabine 11Cyclophosphamide 11tislelizumab 10Drug Therapy 10Injections 8130-nm albumin-bound paclitaxel 8trastuzumab deruxtecan 7durvalumab 7Ipilimumab 7Folfox protocol 7Albumin-Bound Paclitaxel 7titanium silicide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Stomach Neoplasms × Lapatinib × Clear all
NCT00526669 2016-01-29

Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib

GlaxoSmithKline

Phase 2 Completed
68 enrolled 16 charts
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Stomach Neoplasms

NCT00486954 2013-06-20

Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer

GlaxoSmithKline

Phase 3 Completed
273 enrolled 53 charts
Gastrointestinal

Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡